Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55


Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J.

J Clin Oncol. 2018 Jul 1;36(19):1941-1948. doi: 10.1200/JCO.2017.76.4258. Epub 2018 Apr 20.


Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M.

JAMA Oncol. 2018 Apr 1;4(4):545-553. doi: 10.1001/jamaoncol.2017.5524.


Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.

Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J.

Ann Oncol. 2018 Feb 1;29(2):504-509. doi: 10.1093/annonc/mdx713.


Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.

Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx137.


Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy.

Sestak I.

Breast Care (Basel). 2017 Jul;12(3):146-151. doi: 10.1159/000477795. Epub 2017 Jun 27. Review.


Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).

Smith SG, Sestak I, Howell A, Forbes J, Cuzick J.

J Clin Oncol. 2017 Aug 10;35(23):2666-2673. doi: 10.1200/JCO.2016.71.7439. Epub 2017 Jun 29.


HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG).

Eur J Cancer. 2017 Jul;79:129-138. doi: 10.1016/j.ejca.2017.03.033. Epub 2017 May 8.


Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.

Cuzick J, Brentnall AR, Segal C, Byers H, Reuter C, Detre S, Lopez-Knowles E, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M.

J Clin Oncol. 2017 Mar;35(7):743-750. doi: 10.1200/JCO.2016.69.8944. Epub 2016 Dec 28.


Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors.

Šestak I, Cuzick J.

Expert Rev Endocrinol Metab. 2016 Sep;11(5):425-432. doi: 10.1080/17446651.2016.1216101. Epub 2016 Jul 31.


IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer.

Lakhanpal R, Sestak I, Shadbolt B, Bennett GM, Brown M, Phillips T, Zhang Y, Bullman A, Rezo A.

Breast. 2016 Oct;29:147-52. doi: 10.1016/j.breast.2016.06.019. Epub 2016 Aug 5.


Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.

Sestak I, Dowsett M, Ferree S, Baehner FL, Cuzick J.

Breast Cancer Res Treat. 2016 Aug;159(1):71-8. doi: 10.1007/s10549-016-3868-y. Epub 2016 Jul 22.


Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.

Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K, Scheer M, Petry C, Cuzick J, Dowsett M.

J Natl Cancer Inst. 2016 Jul 10;108(11). doi: 10.1093/jnci/djw149. Print 2016 Nov.


Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.

Brentnall AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M.

Breast Cancer Res Treat. 2016 Aug;158(3):591-6. doi: 10.1007/s10549-016-3885-x. Epub 2016 Jul 11.


Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.

Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Pruneri G, Leonardi MC, Orecchia R, Galimberti V, Bonanni B, DeCensi A.

Int J Cancer. 2016 Nov 1;139(9):2127-34. doi: 10.1002/ijc.30254. Epub 2016 Jul 19.


Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.

Sestak I, Zhang Y, Schroeder BE, Schnabel CA, Dowsett M, Cuzick J, Sgroi D.

Clin Cancer Res. 2016 Oct 15;22(20):5043-5048. Epub 2016 Jun 1.


Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators.

Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.


Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.

Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J, Cuzick J.

Ann Oncol. 2016 Apr;27(4):575-90. doi: 10.1093/annonc/mdv590. Epub 2015 Dec 8. Review.


Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.

Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J.

J Clin Oncol. 2016 Jan 10;34(2):139-43. doi: 10.1200/JCO.2015.63.4972. Epub 2015 Nov 23.


Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.

Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS.

BMC Med Genomics. 2015 Aug 22;8:54. doi: 10.1186/s12920-015-0129-6.


Impact of preventive therapy on the risk of breast cancer among women with benign breast disease.

Cuzick J, Sestak I, Thorat MA.

Breast. 2015 Nov;24 Suppl 2:S51-5. doi: 10.1016/j.breast.2015.07.013.


Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer.

Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Mallon E, Howell A, Forbes JF, Buzdar A, Cuzick J.

Clin Cancer Res. 2015 Jun 15;21(12):2763-70. doi: 10.1158/1078-0432.CCR-14-2842.


Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J.

Ann Oncol. 2015 Aug;26(8):1685-91. doi: 10.1093/annonc/mdv215. Epub 2015 May 1.


Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial.

Mote PA, Gompel A, Howe C, Hilton HN, Sestak I, Cuzick J, Dowsett M, Hugol D, Forgez P, Byth K, Graham JD, Clarke CL.

Breast Cancer Res Treat. 2015 Jun;151(2):309-18. doi: 10.1007/s10549-015-3397-0. Epub 2015 Apr 28.


Markers for the identification of late breast cancer recurrence.

Sestak I, Cuzick J.

Breast Cancer Res. 2015 Jan 27;17:10. doi: 10.1186/s13058-015-0516-0. Review.


Update on breast cancer risk prediction and prevention.

Sestak I, Cuzick J.

Curr Opin Obstet Gynecol. 2015 Feb;27(1):92-7. doi: 10.1097/GCO.0000000000000153. Review.


Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators.

Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11.


Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R.

Lancet Oncol. 2014 Dec;15(13):1460-8. doi: 10.1016/S1470-2045(14)71035-6. Epub 2014 Nov 11. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587.


Preventative therapies for healthy women at high risk of breast cancer.

Sestak I.

Cancer Manag Res. 2014 Oct 17;6:423-30. doi: 10.2147/CMAR.S55219. eCollection 2014. Review.


Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.

Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M.

J Clin Oncol. 2015 Mar 10;33(8):916-22. doi: 10.1200/JCO.2014.55.6894. Epub 2014 Oct 20.


Localisation microscopy with quantum dots using non-negative matrix factorisation.

Mandula O, Šestak IŠ, Heintzmann R, Williams CK.

Opt Express. 2014 Oct 6;22(20):24594-605. doi: 10.1364/OE.22.024594.


Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A; IBIS-II investigators.

Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12. Erratum in: Lancet. 2014 Mar 22;383(9922):1040. Lancet. 2017 Mar 11;389(10073):1010.


Equine seroprevalence rates as an additional indicator for a more accurate risk assessment of the West Nile virus transmission.

Vignjević G, Vrućina I, Sestak I, Turić N, Bogojević MS, Merdić E.

Coll Antropol. 2013 Sep;37(3):949-56.


Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence.

Allen MD, Thomas GJ, Clark S, Dawoud MM, Vallath S, Payne SJ, Gomm JJ, Dreger SA, Dickinson S, Edwards DR, Pennington CJ, Sestak I, Cuzick J, Marshall JF, Hart IR, Jones JL.

Clin Cancer Res. 2014 Jan 15;20(2):344-57. doi: 10.1158/1078-0432.CCR-13-1504. Epub 2013 Oct 22.


Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M.

Lancet Oncol. 2013 Oct;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.


Factors predicting late recurrence for estrogen receptor-positive breast cancer.

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J.

J Natl Cancer Inst. 2013 Oct 2;105(19):1504-11. doi: 10.1093/jnci/djt244. Epub 2013 Sep 12.


Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.

Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J.

Breast Cancer Res Treat. 2013 Jul;140(2):253-62. doi: 10.1007/s10549-013-2628-5. Epub 2013 Jul 13.


Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J.

J Clin Oncol. 2013 Aug 1;31(22):2783-90. doi: 10.1200/JCO.2012.46.1558. Epub 2013 Jul 1.


Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL; SERM Chemoprevention of Breast Cancer Overview Group.

Lancet. 2013 May 25;381(9880):1827-34. doi: 10.1016/S0140-6736(13)60140-3. Epub 2013 Apr 30. Review.


Sulphur cycling between terrestrial agroecosystem and atmosphere.

Zgorelec Z, Pehnec G, Bašić F, Kisić I, Mesić M, Zužul S, Jurišić A, Sestak I, Vađić V, Cačković M.

Arh Hig Rada Toksikol. 2012 Sep;63(3):301-10. doi: 10.2478/10004-1254-63-2012-2252.


Preventive therapy for breast cancer.

Sestak I, Cuzick J.

Curr Oncol Rep. 2012 Dec;14(6):568-73. doi: 10.1007/s11912-012-0273-5.


The effect of behavioural risk factors on osteoporosis in Irish women.

Cummins NM, Jakeman PM, Sestak I, Murphy N, Carroll P.

Ir J Med Sci. 2013 Mar;182(1):97-105. doi: 10.1007/s11845-012-0840-7. Epub 2012 Jul 28.


Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.

Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A, Cuzick J.

Br J Cancer. 2012 Jul 10;107(2):230-3. doi: 10.1038/bjc.2012.278. Epub 2012 Jun 26.


Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.

Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J.

Breast Cancer Res Treat. 2012 Jul;134(2):727-34. doi: 10.1007/s10549-012-2085-6. Epub 2012 May 16.


ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.

Pinhel I, Hills M, Drury S, Salter J, Sumo G, A'Hern R, Bliss JM, Sestak I, Cuzick J, Barrett-Lee P, Harris A, Dowsett M; NCRI Adjuvant Breast Cancer Trial Management Group.

Breast Cancer Res. 2012 Mar 14;14(2):R46.


CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.

J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6. Erratum in: J Natl Cancer Inst. 2012 Nov 21;104(22):1772.


Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.

Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J.

J Clin Oncol. 2011 Nov 10;29(32):4266-72. doi: 10.1200/JCO.2011.35.5545. Epub 2011 Oct 11.


Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.

Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, Narod SA.

Cancer Treat Rev. 2012 Jun;38(4):318-28. doi: 10.1016/j.ctrv.2011.06.009. Epub 2011 Jul 19. Review.


Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD.

Lancet Oncol. 2011 Jan;12(1):21-9. doi: 10.1016/S1470-2045(10)70266-7. Epub 2010 Dec 7.


Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators.

Lancet Oncol. 2010 Dec;11(12):1135-41. doi: 10.1016/S1470-2045(10)70257-6. Epub 2010 Nov 17.


Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.

Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J.

J Clin Oncol. 2010 Jul 20;28(21):3411-5. doi: 10.1200/JCO.2009.27.2021. Epub 2010 Jun 14.


Supplemental Content

Loading ...
Support Center